Related Experiment Video
Updated: Mar 9, 2026
06:58
Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
Published on: June 25, 2016
20.1K
Carbamazepine-induced angioedema.
Ansha Subramanian1, Mangaiarkkarasi Adhimoolam1, Senthil Gopalakrishnan1
1Department of Pharmacology, Sri Manakula Vinayagar Medical College and Hospital, Puducherry, India.
Journal of Basic and Clinical Pharmacy
|December 22, 2016
Summary
Carbamazepine can cause rare but dangerous angioedema, a swelling reaction. Prompt treatment with antihistamines and drug withdrawal is crucial for patient safety.
Area of Science:
- Pharmacology
- Clinical Medicine
- Adverse Drug Reactions
Background:
- Carbamazepine is a widely used anticonvulsant and mood-stabilizing medication.
- Angioedema is a rare but serious adverse drug reaction.
- The pathophysiology involves mediators like histamine, serotonin, and kinins (bradykinin).
Observation:
- A 34-year-old female patient developed angioedema 24 hours after starting carbamazepine for bipolar disorder.
- The patient presented with localized tissue edema.
- Symptoms were observed following carbamazepine administration.
Findings:
- Carbamazepine administration triggered angioedema in the patient.
- The patient's symptoms resolved rapidly upon antihistamine treatment.
- Discontinuation of carbamazepine was essential for symptom resolution.
Implications:
- Carbamazepine-induced angioedema is a potentially life-threatening condition.
- Immediate medical intervention, including drug withdrawal and antihistamine therapy, is critical.
- Awareness and monitoring are necessary to prevent severe outcomes and mortality.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
880
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
880
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.7K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.7K
01:17Antiepileptic Drugs: Calcium Channel Blockers
1.5K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.5K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.5K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
01:08Antiepileptic Drugs: Sodium Channel Blockers
2.1K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.1K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.1K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K